Does Johnson & Johnson Stock's Valuation Make Sense? Trefis Team Mon, November 16, 2026 at 3:08 AM EST 4 min read JNJ +1.58% ^GSPC -0.40% PFE +0.52% MRK +1.14% LLY +1.64% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
For questions about this article or underlying research, email help@trefis.com.
Johnson & Johnson (JNJ) stock trades at 42.8 times its earnings over the last twelve months. That multiple is about twice the 21.9 for the S&P 500. Charges in the third quarter for the proposed talc litigation resolution and two deals held down that earnings figure. Yet even on sales the shares cost 6.9 times, against 3.2 for the index. So how fast would Johnson & Johnson have to grow just for today's price to hold?
How Fast Would Johnson & Johnson Have To Grow?
At this price, Johnson & Johnson would have to grow its revenue about 7.6% a year for five years, just for the stock to keep its value. That is close to the 7.8% revenue growth it reported over the last twelve months.
Johnson & Johnson's shares are worth $689 billion today. At a mature P/E of 19.1, supporting that value would take $36.1 billion of yearly profit. Earning that profit at a steady net margin of 25.2% would take $143 billion of revenue. That margin sits halfway between the company's average net margin of 21.9% and its peak of 28.5% over the last twelve quarter-ends, leaving out three far higher readings from 2023 and 2024. Revenue was $99.3 billion over the last twelve months. Reaching that revenue by fiscal 2031 would take growth of 7.6% a year. The horizon is five years because today's P/E is 2.24 times the mature one. Under Trefis rules, a ratio of 2 or more, but below 3, sets a five-year horizon.
The horizon, the mature P/E and the steady margin are Trefis assumptions, not company figures. The mature P/E is a mix: 60% from a sector level of 18.0 and the remainder from the stock's own average P/E of 20.7 over the last twelve quarter-ends.
Does Johnson & Johnson's Business Match That Growth?
Management's sales guide is a little below that pace. It expects fiscal 2026 revenue of about $101 billion, 6.9% more than in fiscal 2025. After that year, the company would have to grow about 7.7% a year over the 4.75 years to the third quarter of fiscal 2031, a bit faster than management has guided for 2026.
The profit guide points to a slower pace. Management guided adjusted earnings per share to grow about 2.9% in 2026. Management said that without the Firefly Bio and Cell BioMedicines deals, that growth would approach 9%.
In the latest quarter, the faster growth came from Innovative Medicine, the drug business, with $60.4 billion of the company's $94.2 billion revenue in fiscal 2025. In the third quarter of fiscal 2026, operational sales in that segment grew 7.9%, and its oncology business grew about 17%. MedTech grew 2.5%, short of management's own expectations. Management says the company as a whole has a clear path to double-digit growth by the end of the decade, and said on the October 13, 2026 call that this goal assumes no acquisitions. That is a goal, not a result.
Johnson & Johnson Has To Rebuild Its Profit Margin
The growth Johnson & Johnson would need is most sensitive to its net margin. If the company's net margin stayed at the 16.2% of the last twelve months, Johnson & Johnson would have to grow revenue 17.5% a year at this price. That pace is faster than in any of the last six twelve-month periods.
That 16.2% is low partly because of one quarter. In the third quarter of fiscal 2026, Johnson & Johnson earned $0.21 billion on $6.37 billion of operating income, after the talc and deal charges. On $25.4 billion of revenue, that is a net margin of 0.8%. Even before that quarter, its net margin was 21.8% and 21.9% in the first two quarters of fiscal 2026, below the steady margin assumed here.
The company's sales record is uneven. Johnson & Johnson grew revenue faster than the required pace in only two of the last four twelve-month periods: 8.4% in the twelve months ended October 2023 and the latest year. In the two periods between, growth was 4.8% and 5.1%.
For the price to hold, Johnson & Johnson has to keep sales growing at about its latest pace. The company also must lift its net margin above where it ran even before the third-quarter charges. If the margin stays near today's level, or growth slips back toward its slower years, the company would need more years to grow into its price, and the stock becomes a riskier bet. The net margin in the fourth-quarter report, expected in January, is the figure to watch.
Beyond JNJ: A Systematic Way To Invest
Before you decide on JNJ, consider a better choice. Since its September 2020 launch, the Trefis High Quality (HQ) Portfolio has returned 105%, ahead of a benchmark that combines the S&P 500, S&P MidCap and Russell 2000, without betting on one stock.
Spot an error or want more like this? Tell us in 10 seconds.